The same center is leading another randomized, open-label phase I/II trial (NCT02932826) with the aim to compare, in T1D, the infusion of umbilical cord blood Tregs combined to insulin and insulin therapy alone. The gene discussed is INS; the disease is type 1 diabetes mellitus.